Key indicators: single-crystal X-ray study; T = 100 K; mean (C-C) = 0.001 Å; disorder in main residue; R factor = 0.040; wR factor = 0.111; data-to-parameter ratio = 32.4.
Related literature
For the pharmaceutical applications of triazole compounds, see: Amir & Kumar (2007) ; Clemons et al. (2004) ; Demirbas & Ugurluoglu (2004) ; Demirbas et al. (2002) ; Johnston (2002) ; Shujuan et al. (2004) . For bond-length data, see: Allen et al. (1987) . For hydrogen-bond motifs, see: Bernstein et al. (1995) . For the stability of the temperature controller used for the data collection, see: Cosier & Glazer (1986) .
Experimental
Crystal data C 22 H 26 N 4 OS M r = 394.53 Triclinic, P1 a = 7.9446 (1) Å b = 11.1392 (2) Å c = 12.3797 (2) Å = 77.769 (1) = 79.025 (1) = 80.063 (1) V = 1041.08 (3) Å 3 Z = 2 Mo K radiation = 0.18 mm À1 T = 100 K 0.50 Â 0.27 Â 0.13 mm
Data collection
Bruker SMART APEXII CCD area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2005) T min = 0.918, T max = 0.977 38166 measured reflections 9105 independent reflections 7573 reflections with I > 2(I) R int = 0.029 Refinement R[F 2 > 2(F 2 )] = 0.040 wR(F 2 ) = 0.111 S = 1.03 9105 reflections 281 parameters H atoms treated by a mixture of independent and constrained refinement Á max = 0.65 e Å À3 Á min = À0.29 e Å À3 Table 1 Hydrogen-bond geometry (Å , ). Symmetry codes: (i) Àx; Ày þ 2; Àz þ 1; (ii) Àx þ 1; Ày þ 2; Àz þ 2; (iii) Àx þ 1; Ày þ 1; Àz þ 2; (iv) Àx þ 2; Ày þ 1; Àz þ 1; (v) x À 1; y; z. Cg1 is the centroid of the N1/N2/C2/N3/C1 ring, Cg2 is the centroid of the C4-C9 ring and Cg3 is the centroid of the C16-C21 ring.
Data collection: APEX2 (Bruker, 2005) ; cell refinement: SAINT (Bruker, 2005) ; data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008) ; program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 ).
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Comment
Several compounds containing 1,2,4-triazole rings are well known as drugs. For example, fluconazole is used as an antimicrobial drug (Shujuan et al., 2004) , while vorozole, letrozole and anastrozole are non-steroidal drugs used for the treatment of cancer (Clemons et al., 2004) and loreclezole is used as an anticonvulsant (Johnston 2002) agent. 1,2,4-Triazoles and their derivatives represent an overwhelming and rapidly developing field in modern heterocyclic chemistry. Similarly, ibuprofen belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with antipyretic, anti-inflammatory and analgesic properties (Amir & Kumar, 2007) . Schiff base derivatives of acetic acid hydrazides containing 1,2,4-triazol-5-one ring have displayed antitumor activity against breast cancer, while 2-phenyl ethylidenamino and 2-phenyl ethylamino derivatives of 4-amino-1,2,4-triazol-5-ones have been found to be effective towards non-small cell lung cancer, CNC and breast cancer (Demirbas et al., 2002 (Demirbas et al., , 2004 . Due to the progress that occurs in dealing with the chemistry of substituted 4-amino-1,2,4triazole-3-thiones and their derivatives as well as their biological activities, we synthesized the title compound and herein report its crystal structure.
Bond lengths in the title molecule ( Fig. 1 ) are found to have normal values (Allen et al., 1987) . The triazole ring is planar to within ±0.024 (1) Å. The dihedral angle formed by the triazole (N1/N2/C2/N3/C1) ring with the C4-C9 and C16-C21 benzene rings are 66.85 (3)° and 25.96 (3)°, respectively. The dihedral angle between the two benzene rings of 87.42 (2)°, indicates that these rings are oriented almost perpendicular to each other. An intramolecular C-H···S hydrogen bond generates an S(6) ring motif (Bernstein et al., 1995) .
The crystal packing is stabilized by intermolecular N-H···S hydrogen bonding together with weak C-H···π interactions (Table 1) (Fig 2) .
Experimental
The title compound, a Schiff base, was obtained by refluxing a mixture of 4-amino-5-[1-(4-isobutylphenyl)ethyl]-4H-1,2,4triazole-3-thiol (0.01 mol), 4-methylbenzaldehyde (0.01 mol) in ethanol (50 ml) and 3 drops of concentrated Sulfuric acid for 3 h. The solid product obtained was collected by filtration, washed with ethanol and dried. It was then recrystallized using ethanol. Single crystals suitable for X-ray analysis were obtained by slow evaporation of an ethanol-N,N-dimethyl formamide (DMF) (3:1) solution.
Refinement
The CH(CH 3 ) unit is disordered over two orientations with occupancies of 0.907 (3) and 0.093 (3). N-bound H atoms were located in a difference Fourier map and were refined freely. C-bound H atoms were positioned geometrically [C-H = 0.93-0.97 Å] and refined using a riding model, with U iso (H) = 1.2U eq (C) and 1.5U eq (methyl C). A rotating-group model was used for methyl groups. 
Special details
Experimental. The crystal was placed in the cold stream of an Oxford Cyrosystems Cobra open-flow nitrogen cryostat (Cosier & Glazer, 1986) operating at 100.0 (1) K. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating Rfactors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq Occ. (<1) S1 0.28546 (3) 0.91565 (2) 0.481988 (17) 0.01833 (5) O1 1.15746 (9) 0.44217 (7) 0.65279 (6) 0.02374 (14) N1 0.01719 (10) 0.92699 (7) 0.65460 (6) 
